Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients

Annals of Surgical Oncology

Volumn 21, Issue 13, 2014, Pages 4263-4269

  Rosenthal, Eben L ^a   Chung, Thomas K ^a   Carroll, William R ^a   Clemons, Lisa ^a   Desmond, Renee ^b   Nabell, Lisle ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c Heerskink School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RASH; STOMATITIS; TREATMENT DURATION; VOMITING; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; HEAD AND NECK NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84911977599     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3878-0     Document Type: Article

References (20)

1. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? The Laryngoscope. 2000;110:1–18.
2. Geretschlager A, Bojaxhiu B, Crowe S, et al. Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. Radiat Oncol. 2012;7:175.
3. Chao KS, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;55:312–21.
4. Kostrzewa JP, Lancaster WP, Iseli TA, et al. Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. The Laryngoscope. 2010;120:267–72.
5. Iseli TA, Iseli CE, Rosenthal EL, et al. Postoperative reirradiation for mucosal head and neck squamous cell carcinomas. Arch Otolaryngol Head Neck Surg. 2009;135:1158–64.
6. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579–84.
7. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568–77.
8. Saba N, Hurwitz SJ, Kono S, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase 1b and pharmacokinetic study. Cancer Prev Res (Phila). 2014;7(3):283–291 (In press).
9. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77–85.
10. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10:247–57.
11. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 2007;25:2178–83.
12. Heath CH, Deep NL, Nabell L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat OncolBiol Phys. 2013;85:1275–81.
13. Arias de la Vega F, Contreras J, de Las Heras M, et al. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial. Ann Oncol. 2012;23:1005–9.
14. Dean NR, Sweeny L, Harari PM, et al. Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients. J Wound Care. 2011;20:166–70.
15. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25:953–9.
16. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008;26:5518–23.
17. Ganly I, Patel SG, Matsuo J, et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg. 2006;132:59–66.
18. Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009;115:5723–33.
19. Becker A, van Wijk A, Smit EF, Postmus PE. Side-effects of long-term administration of erlotinib in patients with non–small cell lung cancer. J Thorac Oncol. 2010;5:1477–80.
20. Polychronidou G, Papakotoulas P. Long-term treatment with erlotinib for EGFR wild-type non–small cell lung cancer: a case report. Case Rep Oncol. 2013;6:189–96.